Company · positioning
ModernaIncumbent
Positioned in 3 collision spaces.
3Collision spaces
Nanotechnology×Disease
76.3Index
Owns the most mature LNP-mRNA platform validated in infectious disease at global scale; actively extending into RSV, influenza, HIV, and CMV nanomedicine.
Open collisionNanotechnology×Immunology
54.8Index
Owns one of the world's most advanced LNP-mRNA platforms and is actively developing personalized mRNA cancer vaccines (mRNA-4157/V940) that reprogram tumor-specific immune responses—direct nano-immunology application.
Open collisionTransgene×Nanotechnology
43.7Index
Deep LNP engineering infrastructure built for mRNA; disclosed interest in using the same platform for gene-editing applications beyond vaccines.
Open collision